FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281683532> ?p ?o ?g. }

• W4281683532 endingPage "i131" @default.
• W4281683532 startingPage "i130" @default.
• W4281683532 abstract "Abstract BACKGROUND: Individuals with rhabdoid tumor predisposition syndrome (RTPS1 – SMARCB1, RTPS2 – SMARCA4) have a propensity to develop malignant rhabdoid tumors (MRT). Affected patients typically present &lt; age 12 months with synchronous tumors (SYN) exhibiting an unusually aggressive clinical behavior. Due to the rarity of RTPS, standards for management are evolving. METHODS: Clinical, genetic, and treatment data of 90 patients with RTPS from 16 countries were analyzed (2004 – 2020). Therapy followed the EU-RHAB recommendations. Tumors and matching blood samples were investigated for SMARCB1 and/or SMARCA4 mutations using FISH, MLPA and sequencing. DNA-methylation subgroups were determined using DNA methylation arrays. RESULTS: The median age at diagnosis of 52 girls and 38 boys was 5.5 months (0 – 203). 55.5% (50/90) of patients presented with an atypical teratoid/rhabdoid tumor (ATRT), 23.5% (21/90) demonstrated SYN, and 21% (19/90) extracranial MRT. RTPS1 was present in 84-, RTPS2 in six patients. In 77% (65/84) complete data on SMARCB1 mutational status were generated. Methylation subgroup status was available in 59% (40/68) of ATRT or SYN. The 5-year overall- (OS) and event free survival rates of patients with RTPS1 were 19.8 ± 4.8% and 15 ± 4.2%, respectively. Age &lt; 1 year at diagnosis (10.1±4.3% vs. 46.7±11.1%), presence of SYN (5.3±5.1% vs. 24.8±6%), histological diagnosis (ATRT vs. eMRT/RTK/SYN) (26.8±7.1% vs. 11.9±5.6%), localized disease (34.5±8 vs. 8.3±4.6%), and presence of PGV at C-terminal (33±8.6% vs. 9.4±5.3%) were significant prognostic factors for 5-year OS in univariate analysis. INTERPRETATION: In the largest cohort of patients with RTPS, predictors significant for positive outcome could be detected: age &gt; 1 year, absence of SYN, histological diagnosis ATRT, localized disease and PGV located at C-terminal. In our research project, we aim to characterize the complete pheno- and genotype of patients with RTPS to develop a risk score including surveillance recommendation." @default.
• W4281683532 created "2022-06-13" @default.
• W4281683532 creator A5002144514 @default.
• W4281683532 creator A5004458972 @default.
• W4281683532 creator A5007763268 @default.
• W4281683532 creator A5008479564 @default.
• W4281683532 creator A5008845970 @default.
• W4281683532 creator A5009575624 @default.
• W4281683532 creator A5013855100 @default.
• W4281683532 creator A5014081389 @default.
• W4281683532 creator A5014361247 @default.
• W4281683532 creator A5017262263 @default.
• W4281683532 creator A5017644585 @default.
• W4281683532 creator A5020380214 @default.
• W4281683532 creator A5020758455 @default.
• W4281683532 creator A5021915690 @default.
• W4281683532 creator A5022584940 @default.
• W4281683532 creator A5023327960 @default.
• W4281683532 creator A5024124953 @default.
• W4281683532 creator A5025548399 @default.
• W4281683532 creator A5033551454 @default.
• W4281683532 creator A5036717623 @default.
• W4281683532 creator A5039047238 @default.
• W4281683532 creator A5041327846 @default.
• W4281683532 creator A5042661460 @default.
• W4281683532 creator A5043717312 @default.
• W4281683532 creator A5047012744 @default.
• W4281683532 creator A5047718521 @default.
• W4281683532 creator A5048993965 @default.
• W4281683532 creator A5049459161 @default.
• W4281683532 creator A5051018235 @default.
• W4281683532 creator A5056055579 @default.
• W4281683532 creator A5057583620 @default.
• W4281683532 creator A5058316194 @default.
• W4281683532 creator A5059673813 @default.
• W4281683532 creator A5059945643 @default.
• W4281683532 creator A5060952957 @default.
• W4281683532 creator A5061634193 @default.
• W4281683532 creator A5069803667 @default.
• W4281683532 creator A5073262158 @default.
• W4281683532 creator A5073481546 @default.
• W4281683532 creator A5075952597 @default.
• W4281683532 creator A5077736287 @default.
• W4281683532 creator A5077767918 @default.
• W4281683532 creator A5079210262 @default.
• W4281683532 creator A5083247482 @default.
• W4281683532 creator A5090007935 @default.
• W4281683532 creator A5091221325 @default.
• W4281683532 creator A5091832008 @default.
• W4281683532 date "2022-06-01" @default.
• W4281683532 modified "2023-10-14" @default.
• W4281683532 title "NFB-13. Rhabdoid Tumor Predisposition Syndrome (RTPS) – Finding Evidence by systematic Analyses" @default.
• W4281683532 doi "https://doi.org/10.1093/neuonc/noac079.475" @default.
• W4281683532 hasPublicationYear "2022" @default.
• W4281683532 type Work @default.
• W4281683532 citedByCount "0" @default.
• W4281683532 crossrefType "journal-article" @default.
• W4281683532 hasAuthorship W4281683532A5002144514 @default.
• W4281683532 hasAuthorship W4281683532A5004458972 @default.
• W4281683532 hasAuthorship W4281683532A5007763268 @default.
• W4281683532 hasAuthorship W4281683532A5008479564 @default.
• W4281683532 hasAuthorship W4281683532A5008845970 @default.
• W4281683532 hasAuthorship W4281683532A5009575624 @default.
• W4281683532 hasAuthorship W4281683532A5013855100 @default.
• W4281683532 hasAuthorship W4281683532A5014081389 @default.
• W4281683532 hasAuthorship W4281683532A5014361247 @default.
• W4281683532 hasAuthorship W4281683532A5017262263 @default.
• W4281683532 hasAuthorship W4281683532A5017644585 @default.
• W4281683532 hasAuthorship W4281683532A5020380214 @default.
• W4281683532 hasAuthorship W4281683532A5020758455 @default.
• W4281683532 hasAuthorship W4281683532A5021915690 @default.
• W4281683532 hasAuthorship W4281683532A5022584940 @default.
• W4281683532 hasAuthorship W4281683532A5023327960 @default.
• W4281683532 hasAuthorship W4281683532A5024124953 @default.
• W4281683532 hasAuthorship W4281683532A5025548399 @default.
• W4281683532 hasAuthorship W4281683532A5033551454 @default.
• W4281683532 hasAuthorship W4281683532A5036717623 @default.
• W4281683532 hasAuthorship W4281683532A5039047238 @default.
• W4281683532 hasAuthorship W4281683532A5041327846 @default.
• W4281683532 hasAuthorship W4281683532A5042661460 @default.
• W4281683532 hasAuthorship W4281683532A5043717312 @default.
• W4281683532 hasAuthorship W4281683532A5047012744 @default.
• W4281683532 hasAuthorship W4281683532A5047718521 @default.
• W4281683532 hasAuthorship W4281683532A5048993965 @default.
• W4281683532 hasAuthorship W4281683532A5049459161 @default.
• W4281683532 hasAuthorship W4281683532A5051018235 @default.
• W4281683532 hasAuthorship W4281683532A5056055579 @default.
• W4281683532 hasAuthorship W4281683532A5057583620 @default.
• W4281683532 hasAuthorship W4281683532A5058316194 @default.
• W4281683532 hasAuthorship W4281683532A5059673813 @default.
• W4281683532 hasAuthorship W4281683532A5059945643 @default.
• W4281683532 hasAuthorship W4281683532A5060952957 @default.
• W4281683532 hasAuthorship W4281683532A5061634193 @default.
• W4281683532 hasAuthorship W4281683532A5069803667 @default.
• W4281683532 hasAuthorship W4281683532A5073262158 @default.
• W4281683532 hasAuthorship W4281683532A5073481546 @default.
• W4281683532 hasAuthorship W4281683532A5075952597 @default.
• W4281683532 hasAuthorship W4281683532A5077736287 @default.

• next